Related Experiment Videos
[Clinical evaluation of imipenem/cilastatin sodium in gynecological infection]
The Japanese Journal of Antibiotics
|June 1, 1986
Abstract:
The MK-0787/MK-0791 is a combination of imipenem (a carbapenem antibiotic) and cilastatin sodium (a dehydro peptidase-I inhibitor) in a 1 to 1 ratio, which produces a higher urinary recovery of imipenem than imipenem alone. The MK-0787/MK-0791 was used in 8 female patients with intrapelvic infections. Clinical efficacies were very good in all the patients. There were neither subjective nor objective side effects nor abnormal laboratory findings.
Insights
The combination of imipenem and cilastatin sodium (MK-0787/MK-0791) effectively treated intrapelvic infections in female patients. This antibiotic combination showed excellent clinical efficacy with no reported side effects.
Area of Science:
- Pharmacology
- Infectious Diseases
- Clinical Medicine
Context:
- Intrapelvic infections pose significant clinical challenges.
- Carbapenem antibiotics are crucial for treating severe bacterial infections.
- The combination of imipenem and cilastatin enhances imipenem's pharmacokinetic profile.
Purpose:
- To evaluate the clinical efficacy and safety of MK-0787/MK-0791 in patients with intrapelvic infections.
- To assess the therapeutic benefits of combining imipenem with cilastatin sodium.
Summary:
- MK-0787/MK-0791, a 1:1 ratio of imipenem and cilastatin sodium, was administered to 8 female patients diagnosed with intrapelvic infections.
- The treatment regimen demonstrated excellent clinical efficacy across all participants.
- No subjective or objective side effects were observed, and laboratory findings remained within normal limits.
Impact:
- This study highlights the potential of MK-0787/MK-0791 as a safe and effective treatment option for intrapelvic infections.
- The findings support the use of imipenem/cilastatin combination therapy for improved patient outcomes in specific infection types.
- The favorable safety profile suggests a low risk of adverse events, enhancing its clinical utility.